AR and breast cancer: Severson et al. leveraged the differing hormonal milieus present in male and female breast cancer patients to assess genome-wide binding of ER, AR, PR, and GR, along with FOXA1, GATA3, and the enhancer-enriched histone mark, H3K4me1, in breast tumors from both genders [158].